Clinical Trial Update: Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of a vaccine therapy with or without recombinant interleukin-12 followed by daclizumab in metastatic melanoma was terminated. Results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Daclizumab (daclizumab)
• Interleukin-12 (interleukin-12)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-10-24